Cargando…

Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?

BRCA1, BRCA2, TP53 and ATM gene mutations are the most studied tumour suppressor genes (TSGs) influencing the loco-regional approach to breast cancer (BC). Due to altered radio sensitivity of mutated cancer cells, mastectomy has always been advised in most patients with BC linked to TSGs mutations i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lazzari, Grazia, Buono, Giuseppe, Zannino, Benedetto, Silvano, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126701/ https://www.ncbi.nlm.nih.gov/pubmed/34012291 http://dx.doi.org/10.2147/BCTT.S306075

Ejemplares similares

Investigation of ATM, TP53 and MDM2 polymorphisms and their association with outcome of radiotherapy for prostate cancer
por: Cintra, Hellen S, et al.
Publicado: (2013)

Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk
por: Baynes, Caroline, et al.
Publicado: (2007)

brca2 and tp53 Collaborate in Tumorigenesis in Zebrafish
por: Shive, Heather R., et al.
Publicado: (2014)

Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade
por: Ding, S L, et al.
Publicado: (2004)

Single nucleotide polymorphisms and unacceptable late toxicity in breast cancer adjuvant radiotherapy: a case report
por: Lazzari, Grazia, et al.
Publicado: (2017)

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
por: Cicenas, Jonas, et al.
Publicado: (2017)

Surgery for BRCA, TP53 and PALB2: a literature review
por: Song, Chin-Vern, et al.
Publicado: (2018)

Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer
por: Borcoman, Edith, et al.
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients
por: Lee, Daphne SC, et al.
Publicado: (2012)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
por: Che, Yuxuan, et al.
Publicado: (2023)

A Novel ATM/TP53/p21-Mediated Checkpoint Only Activated by Chronic γ-Irradiation
por: Cao, Lili, et al.
Publicado: (2014)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
por: Kim, Jin-Ah, et al.
Publicado: (2023)

Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations
por: Kim, Jinyong, et al.
Publicado: (2023)

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent
por: Cavallone, Luca, et al.
Publicado: (2008)

Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil
por: Carraro, Dirce Maria, et al.
Publicado: (2013)

Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population
por: Felix, Gabriela ES, et al.
Publicado: (2014)

Association of ATM, CDH1 and TP53 genes polymorphisms with familial breast cancer in patients of Khyber Pakhtunkhwa, Pakistan
por: Rahim, Abdur, et al.
Publicado: (2022)

BRCA1 and TP53 codeficiency causes a PARP inhibitor–sensitive erythroproliferative neoplasm
por: Lopez-Perez, Gerardo, et al.
Publicado: (2022)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Radiation Recall Pneumonitis COVID-19 Infection Induced After Adjuvant Breast Cancer Radiotherapy. A Known Phenomenon in an Unknown Pandemic Disease: A Case Report
por: Lazzari, Grazia, et al.
Publicado: (2022)

Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy
por: Pan, Yi-Hui, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

RADIATION RECALL PNEUMONITIS COVID-19 INDUCED AFTER ADJUVANT BREAST CANCER RADIOTHERAPY: A CASE REPORT
por: LAZZARI, G., et al.
Publicado: (2022)

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Sinilnikova, O M, et al.
Publicado: (2009)

Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations
por: Kim, Kyung Hwan, et al.
Publicado: (2022)

Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
por: Puiggros, Anna, et al.
Publicado: (2017)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
por: Knappskog, Stian, et al.
Publicado: (2012)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2018)

TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells
por: Anbalagan, Selvakumar, et al.
Publicado: (2021)

Wip1 and ATM in tumor evolution: role for BRCA1
por: Filipponi, Doria, et al.
Publicado: (2013)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

VMAT radiation-induced nausea and vomiting in adjuvant breast cancer radiotherapy: The incidental effect of low-dose bath exposure
por: Lazzari, G., et al.
Publicado: (2017)

Impact on breast cancer susceptibility and clinicopathological traits of common genetic polymorphisms in TP53, MDM2 and ATM genes in Sardinian women
por: Floris, Matteo, et al.
Publicado: (2022)

Oral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancer
por: Perri, Francesco, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5j912d3vv0ak66dka99d90nh15